The inhibitors of
monoamine oxidase B (
MAO B) are effectively used as therapeutic drugs for neuropsychiatric and
neurodegenerative diseases. However, their mechanism of action is not clear, since the
neuroprotective effect of
MAO B inhibitors is associated with the blockage of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-death cascade, rather than the inhibition of
MAO B. Here, we provide evidence that GAPDH potentiates the
ethanol-induced activity of
MAO B and brain cell toxicity. The levels of nuclear GAPDH and
MAO B activity are significantly increased in brain-derived cell lines upon 75 mM
ethanol-induced cell death. Over-expression of GAPDH in cells enhances
ethanol-induced cell death, and also increases the
ethanol-induced activation of
MAO B. In contrast, the
MAO B inhibitors
rasagiline and
selegiline (0.25 nM) and the
rasagiline metabolite, 1-R-aminoindan (1 muM) decreases the
ethanol-induced
MAO B, prevents nuclear translocation of GAPDH and reduces cell death. In addition, GAPDH interacts with
transforming growth factor-beta-inducible early gene (TIEG2), a transcriptional activator for
MAO B, and this interaction is increased in the nucleus by
ethanol but reduced by
MAO B inhibitors and 1-R-aminoindan. Furthermore, silencing TIEG2 using RNAi significantly reduces GAPDH-induced
MAO B upregulation and neurotoxicity. In summary,
ethanol-induced cell death, attenuated by
MAO B inhibitors, may result from disrupting the movement of GAPDH with the transcriptional activator into the nucleus and secondly inhibit
MAO B gene expression. Thus, the
neuroprotective effects of
rasagiline or 1-R-aminoindan on
ethanol-induced cell death mediated by a novel GAPDH-
MAO B pathway may provide a new insight in the treatment of neurobiological diseases including
alcohol-use disorders.